Daprodustat US approval in question after vada CRL; Akebia post-CRL investor call highlights
Following the vadadustat CRL issued on March 30, 2022, Akebia hosted a call with investors to discuss the steps forward. Below FENIX provides highlights and insights from the call, including readthrough to GSK’s daprodustat.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.